Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Asahi Kasei Offshoot to Develop Cancer Vaccine Using Proprietary DDS Base
October 11, 2024
- Ono Snags Worldwide Rights to LigaChem’s ADC Assets
October 11, 2024
- Incubation JV of Takeda, Astellas, SMBC Boots Up in Japan
October 11, 2024
- Opdivo Approved for 1st Line Bladder Cancer Use in Taiwan: Ono
October 11, 2024
- Meiji Rebuts Nursing Group’s Claim on Concerns over Kostaive
October 10, 2024
- Viatris to Discontinue 36 Products/22 APIs in Portfolio Overhaul
October 10, 2024
- Negative Impact of Rumors on Kostaive Is Immense: Meiji Pharma President
October 9, 2024
- Pfizer Curbs Supply of Avastin Biosimilar, 2 Others Hit by Knock-On Effect
October 9, 2024
- Eisai Eyes 2 Trillion Yen Sales Mark by FY2032 with Leqembi as Driver
October 9, 2024
- Eisai’s Gout Drug Urece Approved in Thailand
October 9, 2024
- Astellas, AviadoBio Sign Dementia Gene Therapy Deal
October 9, 2024
- Novartis Launches Another Recall of Comtan over Nitrosamine Impurities
October 9, 2024
- J-TEC to Launch Jacemin Cell Sheet for Vitiligo on Oct. 11
October 8, 2024
- Supply Curb Hits New Generic of Hirudoid Lotion, Demand Driven by Elective Care?
October 8, 2024
- Hisamitsu on Hunt for External Partners to Replenish Pipeline
October 8, 2024
- Japan Ethical Drug Sales Down 3.6% in August: Crecon
October 8, 2024
- Keytruda Best-Seller for 12th Month in September: Encise
October 8, 2024
- Japan's 1st Nasal Flu Vaccine Now Available: Daiichi Sankyo
October 7, 2024
- MSD Curbs Supply of HPV Vaccines in Japan amid Catch-Up Demand
October 7, 2024
- Enhertu Filed for HER2 Low or Ultralow Breast Cancer in Japan
October 7, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…